Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program

被引:177
作者
Garcia-Tsao, Guadalupe [1 ,2 ]
Lim, Joseph [1 ,2 ]
机构
[1] Dept Vet Affairs Med Ctr, West Haven, CT USA
[2] Yale Univ, New Haven, CT USA
关键词
SPONTANEOUS BACTERIAL PERITONITIS; INTRAHEPATIC PORTOSYSTEMIC SHUNT; RANDOMIZED CONTROLLED-TRIAL; INDUCED CIRCULATORY DYSFUNCTION; ENDOSCOPIC VARICEAL LIGATION; PROPRANOLOL PLUS ISOSORBIDE-5-MONONITRATE; EXTRACORPOREAL ALBUMIN DIALYSIS; VASOPRESSIN RECEPTOR ANTAGONIST; PRETRANSPLANT RENAL-FUNCTION; TYPE-1; HEPATORENAL-SYNDROME;
D O I
10.1038/ajg.2009.191
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Cirrhosis represents the end stage of any chronic liver disease. Hepatitis C and alcohol are currently the main causes of cirrhosis in the United States. Although initially cirrhosis is compensated, it eventually becomes decompensated, as defined by the presence of ascites, variceal hemorrhage, encephalopathy, and/or jaundice. These management recommendations are divided according to the status, compensated or decompensated, of the cirrhotic patient, with a separate section for the screening, diagnosis, and management of hepatocellular carcinoma (HCC), as this applies to patients with both compensated and decompensated cirrhosis. In the compensated patient, the main objective is to prevent variceal hemorrhage and any practice that could lead to decompensation. In the decompensated patient, acute variceal hemorrhage and spontaneous bacterial peritonitis are severe complications that require hospitalization. Hepatorenal syndrome is also a severe complication of cirrhosis but one that usually occurs in patients who are already in the hospital and, as it represents an extreme of the hemodynamic alterations that lead to ascites formation, it is placed under treatment of ascites. Recent advances in the pathophysiology of the complications of cirrhosis have allowed for a more rational management of cirrhosis and also for the stratification of patients into different risk groups that require different management. These recommendations are based on evidence in the literature, mainly from randomized clinical trials and meta-analyses of these trials. When few or no data exist from well-designed prospective trials, emphasis is given to results from large series and consensus conferences with involvement of recognized experts. A rational management of cirrhosis will result in improvements in quality of life, treatment adherence, and, ultimately, in outcomes.
引用
收藏
页码:1802 / 1829
页数:28
相关论文
共 258 条
  • [1] Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study
    Abecasis, R
    Kravetz, D
    Fassio, E
    Ameigeiras, B
    Garcia, D
    Isla, R
    Landeira, G
    Dominguez, N
    Romero, G
    Argonz, J
    Terg, R
    [J]. HEPATOLOGY, 2003, 37 (02) : 359 - 365
  • [2] Propranolol for the prevention of first esophageal variceal hemorrhage:: A lifetime commitment?
    Abraczinskas, DR
    Ookubo, R
    Grace, ND
    Groszmann, RJ
    Bosch, J
    Garcia-Tsao, G
    Richardson, CR
    Matloff, DS
    Rodés, J
    Conn, HO
    [J]. HEPATOLOGY, 2001, 34 (06) : 1096 - 1102
  • [3] Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy
    Abraldes, Juan G.
    Villanueva, Candid
    Banares, Rafael
    Aracil, Carles
    Catalina, Maria Vega
    Garcia-Pagan, Juan Carlos
    Bosch, Jaime
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 (02) : 229 - 236
  • [4] Acevedo J, 2009, J HEPATOL S1, V50
  • [5] A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites
    Albillos, A
    Bañares, R
    González, M
    Catalina, MV
    Molinero, LM
    [J]. JOURNAL OF HEPATOLOGY, 2005, 43 (06) : 990 - 996
  • [6] Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study
    Alessandria, C.
    Ottobrelli, A.
    Debernardi-Venon, W.
    Todros, L.
    Cerenzia, M. Torrani
    Martini, S.
    Balzola, F.
    Morgando, A.
    Rizzetto, M.
    Marzano, A.
    [J]. JOURNAL OF HEPATOLOGY, 2007, 47 (04) : 499 - 505
  • [7] Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials
    Als-Nielsen, B
    Gluud, LL
    Gluud, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7447): : 1046 - 1050
  • [8] ALSNIELSEN B, 2004, COCHRANE DB SYST REV, V4, P2798
  • [9] Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
    Angeli, P
    Volpin, R
    Gerunda, G
    Craighero, R
    Rone, P
    Merenda, R
    Amodio, P
    Sticca, A
    Caregaro, L
    Maffei-Faccioli, A
    Gatta, A
    [J]. HEPATOLOGY, 1999, 29 (06) : 1690 - 1697
  • [10] Acute effects of the oral administration of midodrine, an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites
    Angeli, P
    Volpin, R
    Piovan, D
    Bortoluzzi, A
    Craighero, R
    Bottaro, S
    Finucci, GF
    Casiglia, E
    Sticca, A
    De Toni, R
    Pavan, L
    Gatta, A
    [J]. HEPATOLOGY, 1998, 28 (04) : 937 - 943